太极TAIJI品牌怎么样 申请店铺

我要投票 太极TAIJI在乌鸡白凤丸行业中的票数:75 更新时间:2024-12-26
太极TAIJI是哪个国家的品牌?「太极TAIJI」是重庆太极实业(集团)股份有限公司旗下著名品牌。该品牌发源于重庆,由创始人白礼西在1992期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。
太极TAIJI怎么样

太极集团有限公司(简称太极集团)是中国企业500强之一,中国医药工业10强,资产200亿元,拥有“太极集团”(重庆太极实业(集团)股份有限公司)、“桐君阁”(重庆桐君阁股份有限公司)两家上市公司。“太极”(TAIJI)为中国首批驰名保护,OTC品牌药企第一名,2014年集团销售总额达230亿元,2021年将跨越千亿大关。

太极集团拥有10000家药房、13000名员工、20多家医药商业公司、13家制药厂及太极医药研究院、重庆中药研究院两大研发机构。1998年,太极集团与国内外15所院校合作建立博士后工作站;1999年,太极集团技术中心被认定为国家级企业技术中心;2013年,获国家批准建立太极院士专家工作站,中国工程院近20位院士成为太极研发顾问。

太极集团现有中西药品种1500多个、全国独家生产品种50多个、获得国家中药保护品种50多个、国家基药品种165个,获国家专利120项、年销售额逾亿元的品种15个。

太极集团的快速发展主要得益于日益增强的科研开发能力,日益完善的国内市场网络,日益成熟的信息化管理,先进的生产装备,畅销的外贸营销渠道,一流的员工队伍和管理团队,颇具中国特色的管理经验。更为重要的是,太极员工多年受“忠诚、责任、团结、努力”的太极精神熏陶,充满了“光大太极、振兴中华”的必胜信念。

习近平、张德江、江泽民、李鹏、温家宝、吴邦国、曾庆红、邹家华等党和国家领导人多次亲临太极集团视察工作,充分肯定太极集团的发展壮大之路,江泽民同志亲笔书写“太极集团”四个金光闪闪的大字予以鼓励。

阴阳互根方能相长,阴阳平衡万事万物方能和谐发展。太极集团渴望交流,期待合作,愿和您为中国医药事业走向世界而共同努力!

太极急支糖浆

批准文号:国药准字Z33020852

药品规格:每瓶装100毫升、200毫升

功能与主治:清热化痰、宣肺止咳。用于外感风热所致的咳嗽,症见发热、恶寒、胸膈满闷、咳嗽咽痛;急性支气管炎、慢性支气管炎急性发作见上述症候者。

用法与用量:口服。一次20~30ml,一日3~4次;儿童一岁以内一次5ml,一岁至三岁一次7ml,三岁至七岁一次10ml,七岁以上一次15ml,一日3~4次。

生产厂家:太极集团浙江东方制药有限公司

太极天胶

批准文号:国药准字Z62021196

药品规格:250克/盒

功能与主治:补血滋阴,润燥,止血。用于血虚萎黄,眩晕心悸,心烦不眠,肺燥咳嗽。

用法与用量:烊化兑服,3—9克

生产厂家:太极集团甘肃天水羲皇阿胶有限公司

Taiji Group Co., Ltd. (hereinafter referred to as Taiji Group) is one of the top 500 Chinese enterprises, one of the top 10 Chinese pharmaceutical industries, with assets of 20 billion yuan. It has two listed companies, Taiji Group (Chongqing Taiji industry (Group) Co., Ltd.) and TongJunGe (Chongqing TongJunGe Co., Ltd.). Taiji is one of the first batch of well-known protection companies in China, and the first OTC brand pharmaceutical enterprise. In 2014, the group's total sales reached 23 billion yuan, and in 2021, it will surpass 100 billion. Taiji Group has 10000 pharmacies, 13000 employees, more than 20 pharmaceutical commercial companies, 13 pharmaceutical factories, Taiji Pharmaceutical Research Institute and Chongqing Traditional Chinese Medicine Research Institute. In 1998, Taiji Group cooperated with 15 universities at home and abroad to establish a postdoctoral workstation; in 1999, Taiji Group Technology Center was recognized as a national enterprise technology center; in 2013, Taiji Group Technology Center was approved by the state to establish a Taiji academician expert workstation, and nearly 20 academicians of Chinese Academy of Engineering became Taiji R & D consultants. Taiji Group has more than 1500 varieties of Chinese and Western medicine, more than 50 national exclusive production varieties, more than 50 national protected varieties of traditional Chinese medicine, 165 national basic medicine varieties, 120 national patents, and 15 varieties with annual sales of more than 100 million yuan. The rapid development of Taiji Group is mainly due to the increasing research and development ability, the increasingly perfect domestic market network, the increasingly mature information management, advanced production equipment, the best-selling foreign trade marketing channels, the first-class staff and management team, and quite unique management experience in China. What's more, Taiji employees have been influenced by Taiji spirit of "loyalty, responsibility, unity and hard work" for many years, and are full of the belief of "Everbright Taiji and rejuvenation of China". Xi Jinping, Zhang Dejiang, Jiang Zemin, Li Peng, Wen Jiabao, Wu Bangguo, Zeng Qinghong, Zeng Qinghong and other party and state leaders visited Tai Chi Group for many times to inspect the work of Taiji group and fully affirmed the development and expansion of Taiji group. Comrade Hu personally wrote the four golden glittering characters of Taiji group to encourage them. Only when Yin and yang are mutually rooted can they grow, and when Yin and yang balance everything, can everything develop harmoniously. Taiji Group is eager to communicate and cooperate with you. We are willing to work with you for the development of Chinese medicine in the world! Approval No. of taijijijizhi syrup: gyzz z33020852 drug specification: 100ml and 200ml per bottle function and indications: clearing heat and resolving phlegm, promoting lung and relieving cough. It is used for cough caused by exogenous wind heat. Symptoms include fever, cold, chest and diaphragm fullness, cough and sore throat; acute bronchitis and chronic bronchitis with acute attack. Usage and dosage: oral. 20-30ml for one time, 3-4 times a day; 5ml for children under one year old, 7ml for children from one to three years old, 10ml for children from three to seven years old, 15ml for children over seven years old, 3-4 times a day. Manufacturer: Taiji Tianjiao of Zhejiang Oriental Pharmaceutical Co., Ltd. of Taiji group approval No.: gyzz z62021196 drug specification: 250G / box function and indications: nourishing blood and Yin, moistening dryness, hemostasis. It is used for deficiency of blood, yellowing, vertigo, palpitation, restlessness, lung dryness and cough. Usage and dosage: shunyua mixed service, 3-9g manufacturer: Taiji Group Gansu Tianshui Xihuang donkey hide gelatin Co., Ltd

本文链接: https://brand.waitui.com/0814962ca.html 联系电话:023-72800072

千城特选小程序码

7×24h 快讯

百大集团:持有较大金额的金融资产,可能面临资产价值下跌的风险

36氪获悉,百大集团公告,截至2024年12月26日收盘,公司股票价格为11.09元/股,静态市盈率为307.45倍。根据中证指数官网发布的中上协行业分类市盈率显示,公司所属的行业分类“F52 零售业”最新的静态市盈率为24.76倍,公司市盈率明显高于所处行业的平均水平。2024年12月26日,公司股票换手率为8.02%,存在换手率较高的风险。公司持有较大金额的金融资产,资产价格随市场波动较大,可能面临资产价值下跌的风险。

2小时前

通宇通讯:拟出资3000万元参股鸿擎科技以取得1.83%股权

36氪获悉,通宇通讯公告,近日公司与北京昆仑互联网智能产业投资基金合伙企业 (有限合伙)、北京市先进制造和智能装备产业投资基 金(有限合伙)参与北京蓝箭鸿擎科技有限公司(简称“鸿擎科技”)的A1轮融资。公司以自有资金出资3000万元,认缴鸿擎科技新增注册资本51.56万元,剩余部分计入资本公积,以取得本次增资完成后鸿擎科技的1.83%股权。通过此次投资,公司有望借助卫星通信领域的先进技术与广阔市场前景,拓宽业务边界,提升综合竞争力实现资源整合与优势互补。

2小时前

内蒙古河套盆地原油年产量首次突破100万吨

从内蒙古巴彦淖尔市政府获悉,截至12月26日11时,内蒙古河套盆地巴彦油田原油年产量首次突破100万吨,达100.19万吨,进一步夯实当地油藏稳产基础。(新华社)

2小时前

中国神华:子公司取得东胜东至台格庙铁路项目核准批复,项目总投资约113.47亿元

36氪获悉,中国神华公告,近日,公司东胜东至台格庙铁路项目取得内蒙古自治区发展改革委核准批复。东胜东至台格庙铁路项目位于内蒙古自治区鄂尔多斯市伊金霍洛旗和康巴什区,自海勒斯壕南站起至台格庙矿区月牙树湾装车站。正线全长97.611公里,联络线长8.915公里,联络线分别连接巴准、包神等铁路,是新街台格庙矿区及附近煤矿煤炭外运的主要运输通道。项目总投资约为113.47亿元。

2小时前

*ST有树:申请撤销公司股票因重整而被实施退市风险警示,继续被实施退市风险警示及其他风险警示

36氪获悉,*ST有树公告,公司于2024年12月25日收到长沙中院送达的《民事裁定书》,法院裁定确认公司重整计划执行完毕并终结公司重整程序。公司因被法院裁定受理重整而触及的退市风险警示情形已经消除,已向深交所申请撤销相应的退市风险警示。深交所将在收到公司申请后十五个交易日内做出决定。

2小时前

本页详细列出关于中联的品牌信息,含品牌所属公司介绍,中联所处行业的品牌地位及优势。
咨询